24 April 2015
Marinus Pharmaceuticals (NASDAQ:MRNS) insider Gail M. Farfel sold 30,000 shares of Marinus Pharmaceuticals stock on the open market in a transaction that occurred on Tuesday, April 21st. The stock was sold at an average price of $9.48, for a total value of $284,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Separately, analysts at Oppenheimer reiterated an “outperform” rating and set a $12.00 price target on shares of Marinus Pharmaceuticals in a research note on Monday, March 16th.
Shares of Marinus Pharmaceuticals (NASDAQ:MRNS) traded up 1.22% on Friday, hitting $9.15. 3,750 shares of the company’s stock traded hands. Marinus Pharmaceuticals has a 52-week low of $4.00 and a 52-week high of $16.60. The stock has a 50-day moving average of $9. and a 200-day moving average of $9.. The company’s market cap is $129.92 million.
Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings data on Thursday, March 12th. The company reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $1.01. Analysts expect that Marinus Pharmaceuticals will post $-1.87 EPS for the current fiscal year.
Marinus Pharmaceuticals, Inc is a clinical stage biopharmaceutical company. The Company is focused on developing and commercializing neuropsychiatric therapeutics. Its clinical stage product candidate, ganaxolone, is a small molecule that is a synthetic analog of allopregnanolone, an endogenous neurosteroid produced in the central nervous system that modulates the brain neurotransmitter gamma-aminobutyric acid (NASDAQ:MRNS).
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Research calls for greater investment in Alzheimer’s clinical trials
03 May 2024
Stress impact on protein particle formation for monoclonal antibody formulation
03 May 2024
Health Ministry registered Russian drug for ankylosing spondylitis
02 May 2024
Production of finished drugs in Russia grew by 13.8%
02 May 2024